stepping into tevas shoes ., page-5

There a few ? marks re the globe business news statment. 1 "Earlier this year, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) cancelled its development agreement with MGVS as part of Teva's strategic review." .... Answer ..I found this !... Teva raises investment in cell therapy co.


Teva is to invest further in MultiGene Vascular Systems, following the completion of its blocked arteries treatment clinical trial.

26 January 12 10:53, Globes' correspondent


Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has exercised its option to make an additional investment in MultiGene Vascular Systems Ltd. (MGVS), which is developing treatments for disorders of the blood vessels, at a company value of $135 million. Teva exercised the option upon the completion of a clinical trial of MGVS's Phase I/IIa clinical trial of its MultiGeneAngio cell therapy-based treatment of chronic critical limb ischemia, a severe form of peripheral artery disease (PAD, or blocked arteries) in the leg.
MultiGeneAngio is composed of a cell suspension of endothelial and smooth muscle cells, which are isolated from a short vein segment removed from the patient's arm under local anesthesia. These cells are then expanded, characterized, and finally gene modified by the transfer of angiogenic genes. The MultiGeneAngio is injected intra-arterially at the site of blockage using a standard diagnostic catheter, in order to expand and create new collateral arteries, thereby improving blood flow to the ischemic limb.

MGVS began the Phase I/IIa safety and efficacy trial of MultiGeneAngio in November 2009.

In October 2009, Teva invested $4 million in MGVS as part of an $8.5 million financing round, at a company value of $20 million, before money.

MGVS's investors are Teva, Aviv Venture Capital, DFJ Tamir Fishman Ventures Ltd. (TASE: TFVC), and Ofer Hi Tech Ltd. On the basis of MGVS's new company value, DFJ Tamir Fishman will report a $9 million capital gain on its holding in the financial report for the fourth quarter of 2011.

Published by Globes [online], Israel business news - www.globes-online.com - on January 26, 2012 ........2 " If Mesoblast signs the agreement with MGVS, its link with Teva will be reestablished. " Answer. we have never broken the Teva MSB link ...... MSB rejects there is an agreement or even dialogue taking place with MGVS of course that is the answer any company must stand by be it true or false , as that is the line the ASX takes if no official statment to the market is made..... Lets hope TEVA and MSB are spinning a web around all the better prospects out there that fit in well with what we do best ... Vin